Literature DB >> 30705853

Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer.

Nagio Takigawa1, Nobuaki Ochi1, Hiromichi Yamane1.   

Abstract

Entities:  

Year:  2018        PMID： 30705853      PMCID： PMC6328705          DOI： 10.21037/tlcr.2018.11.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

1.  A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

Authors:  H Yoshioka; K Azuma; N Yamamoto; T Takahashi; M Nishio; N Katakami; M J Ahn; T Hirashima; M Maemondo; S W Kim; M Kurosaki; S Akinaga; K Park; C M Tsai; T Tamura; T Mitsudomi; K Nakagawa
Journal:  Ann Oncol       Date:  2015-07-07       Impact factor: 32.976

2.  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Joachim von Pawel; Edward G Garmey; Wallace L Akerley; Wolfram Brugger; Dora Ferrari; Yinpu Chen; Daniel B Costa; David E Gerber; Sergey Orlov; Rodryg Ramlau; Susan Arthur; Igor Gorbachevsky; Brian Schwartz; Joan H Schiller
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

3.  Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.

Authors:  Pasi A Jänne; Alice T Shaw; D Ross Camidge; Giuseppe Giaccone; S Martin Shreeve; Yiyun Tang; Zelanna Goldberg; Jean-François Martini; Huiping Xu; Leonard P James; Benjamin J Solomon
Journal:  J Thorac Oncol       Date:  2016-02-18       Impact factor: 15.609

4.  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

Authors:  David R Spigel; Martin J Edelman; Kenneth O'Byrne; Luis Paz-Ares; Simonetta Mocci; See Phan; David S Shames; Dustin Smith; Wei Yu; Virginia E Paton; Tony Mok
Journal:  J Clin Oncol       Date:  2016-12-12       Impact factor: 44.544

5.  Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Giorgio Scagliotti; Joachim von Pawel; Silvia Novello; Rodryg Ramlau; Adolfo Favaretto; Fabrice Barlesi; Wallace Akerley; Sergey Orlov; Armando Santoro; David Spigel; Vera Hirsh; Frances A Shepherd; Lecia V Sequist; Alan Sandler; Jeffrey S Ross; Qiang Wang; Reinhard von Roemeling; Dale Shuster; Brian Schwartz
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

6.  Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Sai-Hong Ignatius Ou; Ramaswamy Govindan; Keith D Eaton; Gregory A Otterson; Martin E Gutierrez; Alain C Mita; Athanassios Argiris; Nicoletta M Brega; Tiziana Usari; Weiwei Tan; Steffan N Ho; Francisco Robert
Journal:  J Thorac Oncol       Date:  2016-09-30       Impact factor: 15.609

7.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Authors:  James Bean; Cameron Brennan; Jin-Yuan Shih; Gregory Riely; Agnes Viale; Lu Wang; Dhananjay Chitale; Noriko Motoi; Janos Szoke; Stephen Broderick; Marissa Balak; Wen-Cheng Chang; Chong-Jen Yu; Adi Gazdar; Harvey Pass; Valerie Rusch; William Gerald; Shiu-Feng Huang; Pan-Chyr Yang; Vincent Miller; Marc Ladanyi; Chih-Hsin Yang; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

8.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

9.  Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.

Authors:  Emily R York; Marileila Varella-Garcia; Tami J Bang; Dara L Aisner; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2017-03-06       Impact factor: 15.609

10.  Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.

Authors:  Koichi Azuma; Tomonori Hirashima; Nobuyuki Yamamoto; Isamu Okamoto; Toshiaki Takahashi; Makoto Nishio; Taizo Hirata; Kaoru Kubota; Kazuo Kasahara; Toyoaki Hida; Hiroshige Yoshioka; Kaoru Nakanishi; Shiro Akinaga; Kazuto Nishio; Tetsuya Mitsudomi; Kazuhiko Nakagawa
Journal:  ESMO Open       Date:  2016-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.